Literature DB >> 15582307

Drug-induced atrial fibrillation.

Cornelis S van der Hooft1, Jan Heeringa, Gerard van Herpen, Jan A Kors, J Herre Kingma, Bruno H Ch Stricker.   

Abstract

Atrial fibrillation (AF) is the most common sustained rhythm disorder observed in clinical practice and predominantly associated with cardiovascular disorders such as coronary heart disease and hypertension. However, several classes of drugs may induce AF in patients without apparent heart disease or may precipitate the onset of AF in patients with preexisting heart disease. We reviewed the literature on drug-induced AF, using the PubMed/Medline and Micromedex databases and lateral references. Successively, we discuss the potential role in the onset of AF of cardiovascular drugs, respiratory system drugs, cytostatics, central nervous system drugs, genitourinary system drugs, and some miscellaneous agents. Drug-induced AF may play a role in only a minority of the patients presenting with AF. Nevertheless, it is important to recognize drugs or other agents as a potential cause, especially in the elderly, because increasing age is associated with multiple drug use and a high incidence of AF. This may contribute to timely diagnosis and management of drug-induced AF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15582307     DOI: 10.1016/j.jacc.2004.08.053

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  27 in total

1.  Zoledronic acid and atrial fibrillation in cancer patients.

Authors:  Cagatay Arslan; Sercan Aksoy; Omer Dizdar; Didem S Dede; Hakan Harputluoglu; Kadri Altundag
Journal:  Support Care Cancer       Date:  2010-04-01       Impact factor: 3.603

2.  Behçet's disease: A (silk) route to atrial fibrillation?

Authors:  Santosh V Suryavanshi; Na Li
Journal:  Int J Cardiol       Date:  2019-07-19       Impact factor: 4.164

Review 3.  Role of late sodium channel current block in the management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Cardiovasc Drugs Ther       Date:  2013-02       Impact factor: 3.727

Review 4.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 5.  Lone AF - Etiologic Factors and Genetic Insights into Pathophysiolgy.

Authors:  Babar Parvez; Dawood Darbar
Journal:  J Atr Fibrillation       Date:  2010-06-01

Review 6.  Structural and Functional Remodeling of the Left Atrium: Clinical and Therapeutic Implications for Atrial Fibrillation.

Authors:  Rajeev Pathak; Dennis H Lau; Rajiv Mahajan; Prashanthan Sanders
Journal:  J Atr Fibrillation       Date:  2013-12-31

Review 7.  Atrial Fibrillation: The New Epidemic of the Ageing World.

Authors:  Wilbert S Aronow; Maciej Banach
Journal:  J Atr Fibrillation       Date:  2009-04-01

Review 8.  Cardiovascular effects of noncardiovascular drugs.

Authors:  Satish R Raj; C Michael Stein; Pablo J Saavedra; Dan M Roden
Journal:  Circulation       Date:  2009-09-22       Impact factor: 29.690

Review 9.  Cardioversion in atrial fibrillation. Focus on recent-onset atrial fibrillation.

Authors:  Andrea Tampieri; Anna Maria Rusconi; Tiziano Lenzi
Journal:  Intern Emerg Med       Date:  2012-10       Impact factor: 3.397

Review 10.  Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.

Authors:  Adriana Albini; Giuseppina Pennesi; Francesco Donatelli; Rosaria Cammarota; Silvio De Flora; Douglas M Noonan
Journal:  J Natl Cancer Inst       Date:  2009-12-10       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.